MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Personalis Operating Cycle 2011-2026 | PSNL
Annual Operating Cycle Personalis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.8 | 85.4 | 98.5 | 53 | 22.4 | 30.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98.5 | 22.4 | 57.6 |
Quarterly Operating Cycle Personalis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.6 | 55.5 | 42.3 | - | 46.8 | 49 | 67.9 | - | 59.5 | 77.1 | 84 | - | 41.7 | 33.8 | 95.8 | - | 40.6 | 36.5 | 31.5 | - | 29.2 | 29.7 | 23 | 16.6 | 17.6 | 19 | 25.1 | 30.9 | 34.9 | 23.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 95.8 | 16.6 | 43.5 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Chembio Diagnostics
CEMI
|
164 | - | 0.22 % | $ 16.8 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
275 | $ 24.45 | 4.28 % | $ 263 M |  China |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
405 | $ 6.05 | 1.09 % | $ 178 M | USA |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M | USA |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
Castle Biosciences
CSTL
|
97.9 | $ 39.32 | -0.86 % | $ 1.09 B | USA |
 |
DexCom
DXCM
|
204 | $ 69.4 | -2.23 % | $ 26.8 B | USA |
 |
BioNano Genomics
BNGO
|
329 | $ 1.6 | 0.63 % | $ 2.03 M | USA |
 |
Guardant Health
GH
|
49.1 | $ 105.93 | -1.52 % | $ 13 B | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
Illumina
ILMN
|
198 | $ 147.9 | 1.61 % | $ 23.5 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
 |
IQVIA Holdings
IQV
|
78 | $ 243.99 | 1.23 % | $ 44.2 B | USA |
 |
CareDx, Inc
CDNA
|
76.4 | $ 20.33 | -1.19 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
150 | $ 239.32 | 0.11 % | $ 175 B | USA |
 |
DarioHealth Corp.
DRIO
|
251 | $ 12.33 | 5.61 % | $ 350 M |  Israel |
 |
Anixa Biosciences
ANIX
|
275 | $ 3.13 | -0.95 % | $ 102 K | USA |
 |
Enzo Biochem
ENZ
|
206 | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
116 | $ 66.82 | -0.98 % | $ 4.62 B | USA |
 |
Exact Sciences Corporation
EXAS
|
269 | $ 102.16 | -0.07 % | $ 18.9 B | USA |
 |
Medpace Holdings
MEDP
|
51.5 | $ 604.32 | 0.85 % | $ 18.7 B | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 28.28 | 0.44 % | $ 855 M | USA |
 |
Aspira Women's Health
AWH
|
73.8 | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
87.1 | $ 6.54 | -0.46 % | $ 593 M | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
33 | $ 20.51 | 0.39 % | $ 503 M | USA |
 |
Natera
NTRA
|
81.5 | $ 235.34 | -0.05 % | $ 23.2 B | USA |
 |
OPKO Health
OPK
|
285 | $ 1.32 | -0.75 % | $ 916 M | USA |
 |
Pacific Biosciences of California
PACB
|
183 | $ 2.11 | 4.98 % | $ 535 M | USA |
 |
Charles River Laboratories International
CRL
|
67.7 | $ 226.77 | 3.57 % | $ 11.7 B | USA |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
Mettler-Toledo International
MTD
|
63.7 | $ 1 506.5 | 0.94 % | $ 32 B |  Schweiz |
 |
ENDRA Life Sciences
NDRA
|
412 | $ 4.41 | -2.22 % | $ 2.37 M | USA |
 |
Invitae Corporation
NVTA
|
368 | - | - | $ 21.2 M | USA |
 |
Neogen Corporation
NEOG
|
213 | $ 9.23 | -1.49 % | $ 2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
56.9 | $ 176.78 | 0.98 % | $ 19.6 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 7.84 | -2.97 % | $ 1.02 B | USA |
 |
Organovo Holdings
ONVO
|
79.8 | - | -2.3 % | $ 19.4 M | USA |